Oral obesity drugs accelerate
The FDA approved a higher-dose semaglutide injection, Wegovy HD, under an accelerated review, and Lilly has launched its oral obesity pill Foundayo—signalling the weight-loss market is shifting from scarce weekly injections toward daily pills and price competition. Companies and channels are already reacting: trial efficacy numbers and new distribution moves are turning access, format and discounts into the central battleground. (ajmc.com) (biospace.com) (eu.usatoday.com)
These drugs started as weekly shots with waiting lists. In April 2026, the fight moved to pills, pharmacy shelves, and discount cards. (fda.gov) (lilly.com) The basic trick is simple: semaglutide and orforglipron copy a gut hormone called glucagon-like peptide-1, which tells the brain you are full and slows how fast food leaves the stomach. That is why people talk about these medicines as appetite drugs even though they started in diabetes care. (fda.gov) (foundayo.lilly.com) For years, the catch was the format. The best-known obesity medicines were injections, usually taken once a week, which made supply, training, and needle aversion part of the business. (usatoday.com) (fda.gov) Now the two biggest names in the market are pushing in opposite directions at once. The Food and Drug Administration approved Wegovy HD, a 7.2 milligram version of Novo Nordisk’s semaglutide shot, while Eli Lilly launched Foundayo, a once-daily obesity pill also known as orforglipron. (fda.gov) (lilly.com) Wegovy HD moved unusually fast. The Food and Drug Administration said the decision came 54 days after filing under the Commissioner’s National Priority Voucher pilot, and the agency called it the fourth approval through that program. (fda.gov) Novo Nordisk is selling that higher dose on one number: 20.7% mean weight loss when trial participants adhered to treatment. That is higher than the 14.9% average weight loss reported in the original STEP 1 trial for the standard 2.4 milligram Wegovy injection. (novonordisk.com) (sciencehub.novonordisk.com) Lilly is selling convenience instead. Foundayo is the only approved weight-loss pill in this class that Lilly says can be taken any time of day without food or water restrictions, which removes the ritual that has made some older oral hormone drugs fussy to use. (lilly.com) (foundayo.lilly.com) Its headline trial result is smaller than Wegovy HD’s, but it comes in a pill. Lilly says adults without type 2 diabetes lost 11.1% of body weight at 72 weeks on the 17.2 milligram dose of Foundayo, versus 2.1% on placebo. (foundayo.lilly.com) That gap is why the market is no longer just about who has the strongest drug. It is about what patients will actually start, what insurers will cover, and what pharmacies can put in someone’s hand this week. (usatoday.com) (lilly.com) The pricing war is already visible. Lilly says Foundayo starts at $25 a month for eligible commercially insured patients and $149 a month for self-pay, and Amazon Pharmacy says it will deliver the pill with same-day service in nearly 3,000 cities and towns. (foundayo.lilly.com) (businesswire.com) Novo Nordisk is reacting through distribution too. It expanded access to semaglutide medicines through Hims & Hers in March, and Weight Watchers now offers the Wegovy pill from $149 per month for a limited-time self-pay offer. (novomedlink.com) (weightwatchers.com) So the new contest looks less like a single horse race and more like three separate ones. Novo Nordisk is pushing higher efficacy with Wegovy HD, Lilly is pushing easier daily use with Foundayo, and Amazon, Hims & Hers, and Weight Watchers are trying to become the front door where people actually get the prescription filled. (fda.gov) (lilly.com) (businesswire.com) (novomedlink.com)
